Faron Pharmaceuticals: Faron Pharmaceuticals Ltd: PDMR Dealing

Faron Pharmaceuticals OyAnnouncement

13/01/2026 16:00

Faron Pharmaceuticals Ltd | Company announcement | January 13, 2026 at
18:00:00 EET

TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a
clinical-stage biopharmaceutical company focused on developing novel
immunotherapies, announces today that Mr. Jurriaan Dekkers, Chief Financial
Officer of the Company, sold 4,000 ordinary shares in Faron at price of £1.822
per share on 12 January 2026.

Further details are set out in the Notification of Dealing Form below.

+------------------+------------+-------------+--------------+---------------+
| PDMR             |    Holding |   Number of |    Resultant |     Resultant |
|                  |   prior to |    ordinary |  interest in | percentage of |
|                  |       sale | shares sold |     ordinary | voting rights |
|                  |            |             |    shares in |        in the |
|                  |            |             |  the Company |       Company |
+------------------+------------+-------------+--------------+---------------+
| Jurriaan Dekkers |      4,000 |       4,000 |            0 |          0.0% |
+------------------+------------+-------------+--------------+---------------+

For more information, please contact:

+-------------------------------------+--------------------------------------+
| IR Partners, Finland                |                                      |
| (Media)                             | +358 50 553 9535 / +44 7 469 766 223 |
|                                     |         kare.laukkanen@irpartners.fi |
| Kare Laukkanen                      |                                      |
|                                     |                                      |
+-------------------------------------+--------------------------------------+
| FINN Partners, US                   |                     +1 847 791-8085  |
| (Media)                             |        alyssa.paldo@finnpartners.com |
| Alyssa Paldo                        |                                      |
|                                     |                                      |
+-------------------------------------+--------------------------------------+
| Cairn Financial Advisers LLP        |                 +44 (0) 207 213 0880 |
| (Nominated Adviser and Broker)      |                                      |
| Sandy Jamieson, Jo Turner           |                                      |
|                                     |                                      |
+-------------------------------------+--------------------------------------+
| Sisu Partners Oy                    |                  +358 (0)40 555 4727 |
| (Certified Adviser on Nasdaq First  |                  +358 (0)50 553 8990 |
| North)                              |                                      |
| Juha Karttunen                      |                                      |
| Jukka Järvelä                       |                                      |
+-------------------------------------+--------------------------------------+

About Faron Pharmaceuticals Ltd.
Faron (AIM: FARN, First North: FARON) is a global, clinical-stage
biopharmaceutical company, focused on tackling cancers via novel
immunotherapies. Its mission is to bring the promise of immunotherapy to a
broader population by uncovering novel ways to control and harness the power
of the immune system. The Company’s lead asset is bexmarilimab, a novel
anti-Clever-1 humanized antibody, with the potential to remove
immunosuppression of cancers through reprogramming myeloid cell
function. Bexmarilimab is being investigated in Phase I/II clinical trials as
a potential therapy for patients with hematological cancers in combination
with other standard treatments. Further information is available
at www.faron.com (http://www.faron.com/).

+--------------+-----------------+-----------------+----------+-----------+--+
| Notification |                 |                 |          |           |  |
| of a         |                 |                 |          |           |  |
| Transaction  |                 |                 |          |           |  |
| pursuant to  |                 |                 |          |           |  |
| Article      |                 |                 |          |           |  |
| 19(1) of     |                 |                 |          |           |  |
| Regulation   |                 |                 |          |           |  |
| (EU) No.     |                 |                 |          |           |  |
| 596/2014     |                 |                 |          |           |  |
+--------------+-----------------+-----------------+----------+-----------+--+
| 1            | Details of the  |                 |          |           |  |
|              | person          |                 |          |           |  |
|              | discharging     |                 |          |           |  |
|              | managerial      |                 |          |           |  |
|              | responsibilities/person |                 |          |           |  |
|              | closely         |                 |          |           |  |
|              | associated      |                 |          |           |  |
+--------------+-----------------+-----------------+----------+-----------+--+
| a.           | Name            | Jurriaan        |          |           |  |
|              |                 | Dekkers         |          |           |  |
+--------------+-----------------+-----------------+----------+-----------+--+
| 2            | Reason for      |                 |          |           |  |
|              | notification    |                 |          |           |  |
+--------------+-----------------+-----------------+----------+-----------+--+
| a.           | Position/Status | Chief Financial |          |           |  |
|              |                 | Officer         |          |           |  |
+--------------+-----------------+-----------------+----------+-----------+--+
| b.           | Initial         | Initial         |          |           |  |
|              | notification/   | Notification    |          |           |  |
|              | Amendment       |                 |          |           |  |
+--------------+-----------------+-----------------+----------+-----------+--+
| 3            | Details of the  |                 |          |           |  |
|              | issuer,         |                 |          |           |  |
|              | emission        |                 |          |           |  |
|              | allowance       |                 |          |           |  |
|              | market          |                 |          |           |  |
|              | participant,    |                 |          |           |  |
|              | auction         |                 |          |           |  |
|              | platform,       |                 |          |           |  |
|              | auctioneer or   |                 |          |           |  |
|              | auction monitor |                 |          |           |  |
+--------------+-----------------+-----------------+----------+-----------+--+
| a.           | Name            | Faron           |          |           |  |
|              |                 | Pharmaceuticals |          |           |  |
|              |                 | Ltd.            |          |           |  |
+--------------+-----------------+-----------------+----------+-----------+--+
| b.           | LEI             |                 |          |           |  |
|              |                 | 7437009H31TO1DC0EB42 |          |           |  |
|              |                 |                 |          |           |  |
+--------------+-----------------+-----------------+----------+-----------+--+
| 4            | Details of the  |                 |          |           |  |
|              | transaction(s): |                 |          |           |  |
|              | section to be   |                 |          |           |  |
|              | repeated for    |                 |          |           |  |
|              | (i) each type   |                 |          |           |  |
|              | of instrument;  |                 |          |           |  |
|              | (ii) each type  |                 |          |           |  |
|              | of transaction; |                 |          |           |  |
|              | (iii) each      |                 |          |           |  |
|              | date; and (iv)  |                 |          |           |  |
|              | each place      |                 |          |           |  |
|              | where           |                 |          |           |  |
|              | transactions    |                 |          |           |  |
|              | have been       |                 |          |           |  |
|              | conducted       |                 |          |           |  |
+--------------+-----------------+-----------------+----------+-----------+--+
| a.           | Description of  | Ordinary Shares |          |           |  |
|              | the financial   |                 |          |           |  |
|              | instrument,     |                 |          |           |  |
|              | type of         |                 |          |           |  |
|              | instrument      | ISIN:           |          |           |  |
|              |                 | FI4000153309    |          |           |  |
|              | Identification  |                 |          |           |  |
|              | Code            |                 |          |           |  |
+--------------+-----------------+-----------------+----------+-----------+--+
| b.           | Nature of the   | Sale of         |          |           |  |
|              | transaction     | Ordinary Shares |          |           |  |
+--------------+-----------------+-----------------+----------+-----------+--+
|              |                 |                 | Price(s) | Volume(s) |  |
|              |                 |                 | per      |           |  |
|              |                 |                 | share    |           |  |
|              |                 |                 | (p)      |           |  |
+--------------+-----------------+-----------------+----------+-----------+--+
|              |                 |                 | £1.822   | 4,000     |  |
|              |                 |                 |          |           |  |
|              |                 |                 |          |           |  |
+--------------+-----------------+-----------------+----------+-----------+--+
|              |                 |                 |          |           |  |
|              |                 |                 |          |           |  |
+--------------+-----------------+-----------------+----------+-----------+--+
| d.           | Aggregated      |                 |          |           |  |
|              | information     |                 |          |           |  |
|              | Volume          |                 |          |           |  |
|              | Price           | 4,000           |          |           |  |
|              |                 | £1.822          |          |           |  |
|              |                 |                 |          |           |  |
+--------------+-----------------+-----------------+----------+-----------+--+
| e.           | Date of the     | 12/01/2026      |          |           |  |
|              | transaction     |                 |          |           |  |
+--------------+-----------------+-----------------+----------+-----------+--+
| f.           | Place of the    | London Stock    |          |           |  |
|              | transaction     | Exchange, AIM   |          |           |  |
+--------------+-----------------+-----------------+----------+-----------+--+